The trial will include patients with non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

The resolution aims to provide Illinois patients with equitable access to emerging treatments, including precision and genomic medicines.

The Shanghai-based firm will test the gene therapy candidate in patients between 4 and 9 years old with Duchenne muscular dystrophy.

NEW YORK – By the end of a controversial workshop Thursday on whether to test patients for genetic abnormalities that put them at risk of severe chemotherapy-related toxicities, oncologists seemed ...

The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

Their study showed that DCIS patients with pathogenic variants in BRCA1/2 and PALB2 had a higher risk of developing invasive breast cancer than those without.

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.